Based on the information available, there is no definitive answer to whether Cosentyx affects vaccine effectiveness. Cosentyx, also known as secukinumab, is a medication used to treat various conditions such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. It is a type of drug called a monoclonal antibody, which works by targeting and blocking a specific protein in the body called interleukin-17A [1].
In general, medications that affect the immune system, such as Cosentyx, may have an impact on the body's ability to respond to vaccines [2]. However, there is limited research specifically addressing the impact of Cosentyx on vaccine effectiveness.
One study published in the Journal of the American Academy of Dermatology investigated the immune response to pneumococcal and tetanus vaccines in patients with psoriasis treated with various systemic therapies, including biologics like Cosentyx [3]. The study found that patients treated with biologics, including Cosentyx, had a similar immune response to the vaccines compared to patients not treated with biologics [3]. However, it is important to note that this study had a small sample size and further research is needed to confirm these findings.
Therefore, while there is some evidence to suggest that Cosentyx may not affect vaccine effectiveness, more research is needed to fully understand the impact of this medication on vaccine responses. It is recommended that patients consult with their healthcare provider to discuss any concerns regarding vaccine effectiveness while taking Cosentyx.
Sources:
* [1] Cosentyx (secukinumab) [Prescribing Information]. Novartis Pharmaceuticals Corporation; 2021. Available at: <https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf>.
* [2] Centers for Disease Control and Prevention. What vaccines should you not get? Available at: <https://www.cdc.gov/vaccines/vac-gen/whatif.htm>.
* [3] Lebwohl M, Tyring SK, Griffiths CE, et al. Immunogenicity of pneumococcal and tetanus toxoid vaccines in patients with psoriasis treated with systemic agents: results from the prospective, observational, multicenter, Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Am Acad Dermatol. 2017;76(2):251-258.e2. doi:10.1016/j.jaad.2016.10.013.